HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

2- (4- bromophenyl)- 6- methyl- N- (2- (1- oxidopyridin- 3- yl)ethyl)pyrimidin- 4- amine

a GPR119 agonist; structure in first source

Also Known As:

AS 1535907; AS-1535907; AS1535907

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - 2-(4-bromophenyl)-6-methyl-N-(2-(1-oxidopyridin-3-yl)ethyl)pyrimidin-4-amine: 2
- Heterocyclic Oxides
  - Cyclic N-Oxides: 3
    - 2-(4-bromophenyl)-6-methyl-N-(2-(1-oxidopyridin-3-yl)ethyl)pyrimidin-4-amine: 2

Experts

1.	Matsui, T: 1 article (01/2011)
2.	Ohishi, T: 1 article (01/2011)
3.	Oshima, H: 1 article (01/2011)
4.	Shibasaki, M: 1 article (01/2011)
5.	Tanaka, H: 1 article (01/2011)
6.	Yonetoku, Y: 1 article (01/2011)
7.	Yoshida, S: 1 article (01/2011)
8.	Matsui, Tetsuo: 1 article (11/2010)
9.	Ohishi, Takahide: 1 article (11/2010)
10.	Oshima, Hiroyuki: 1 article (11/2010)

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 01/01/2011 - "AS1535907, a small molecule agonist of GPR119, was assessed for its glucose-stimulated insulin secretory activity and pancreatic β-cell function in type 2 diabetes. " 11/12/2010 - "In conclusion, the GPR119 agonist AS1535907 induces a more rapid and physiological pattern of insulin release than glibenclamide, and represents a novel strategy for the treatment of type 2 diabetes."
2.	Hypoglycemia (Reactive Hypoglycemia) 11/12/2010 - "These results demonstrate that GPR119 agonist AS1535907 has the ability to stimulate the first phase of GSIS, which is important for preventing the development of postprandial hypoglycemia. "

Related Drugs and Biologics

1.	Insulin (Novolin)
2.	Glucose (Dextrose)
3.	Glyburide (Glibenclamide)